Palivizumab - CISMeF

Preferred Label : Palivizumab;

NCIt definition : A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.;

UNII : DQ448MW7KS;

CAS number : 188039-54-5;

Drug name : Synagis;

Molecule name : MEDI 493;

Details

Origin ID

C2625;

UMLS CUI

C0672596;

CISMeF manual mappings
- Palivizumab [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing palivizumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Palivizumab [MeSH Descriptor]
- Palivizumab (substance) [SNOMED CT concept]
- Product containing palivizumab (medicinal product) [SNOMED CT concept]
- palivizumab [ATC Code]
- palivizumab [International Nonproprietary Name]
- palivizumab [MeSH concept]
Validated automatic mappings to BTNT
- palivizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
is_component_of_chemotherapy_regimen
- Palivizumab/Ribavirin [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients